Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, announced that it has launched ZYFLO CR(TM) (zileuton) extended release tablets with its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX). ZYFLO CR(TM) offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older. [click link for full article]
(more...)